SPS
MLYS icon

Susquehanna Portfolio Strategies’s Mineralys Therapeutics MLYS Stock Holding History

Susquehanna Portfolio Strategies’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-78,092
Closed -$2.12M – 999
2026
Q1 		$2.12M Hold
78,092
– – 0.03% 487
2025
Q4 		$2.83M Hold
78,092
– – 0.04% 430
2025
Q3 		$2.96M Sell
78,092
-83,042
-52% -$1.8M 0.05% 423
2025
Q2 		$2.18M Buy
161,134
+142,889
+783% +$2.07M 0.05% 354
2025
Q1 		$290K Buy
+18,245
New +$210K 0.12% 101

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $229M AUM 100.3% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Susquehanna Portfolio Strategies's MLYS Position: Q2 2026 in Review

Susquehanna Portfolio Strategies sold out of Mineralys Therapeutics (MLYS) in Q2 2026, closing a stake of 78,092 shares — an estimated $2.12M sold.

Susquehanna Portfolio Strategies first reported a position in MLYS in Q1 2025 and held it in 5 quarters. The position peaked at $2.96M in Q3 2025. 224 funds tracked by Wall St. Rank hold MLYS as of Q2 2026.

  • Susquehanna Portfolio Strategies reported no remaining Mineralys Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Susquehanna Portfolio Strategies sold 78,092 Mineralys Therapeutics shares in Q2 2026, an estimated $2.12M.
  • Susquehanna Portfolio Strategies first reported a position in Mineralys Therapeutics in Q1 2025 and held it in 5 quarters.
  • Susquehanna Portfolio Strategies's Mineralys Therapeutics position peaked at $2.96M in Q3 2025.
  • 224 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q2 2026.

Based on Susquehanna Portfolio Strategies's 13F filing for Q2 2026, filed 14 Aug 2026.